top of page
For most cost-effective consulting services:
Click here
Home
All News
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
About
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
China’s Biotech Momentum Grows as Pfizer Signs Multi-Billion Dollar Deal with Innovent | iPharmaCenter
Badari Andukuri
May 29
Imfinzi Secures US Approval as First Immunotherapy Combination for High-Risk NMIBC | iPharmaCenter
Badari Andukuri
May 29
CVS Caremark Shakes Up GLP-1 Coverage as Zepbound Returns to the Formulary | iPharmaCenter
Badari Andukuri
May 28
FDA Clears Decnupaz (pivekimab sunirine) for Adults With BPDCN | iPharmaCenter
Badari Andukuri
May 28
SFDA Grants Promising Drug Status to Novo Nordisk’s Frehemgo for Hemophilia A | iPharmaCenter
Badari Andukuri
May 28
Spain Explores Italy’s HTA Model to Advance EU HTA Regulation Implementation | iPharmaCenter
Badari Andukuri
May 27
AIFA Innovative Drugs April 2026: Opdivo, Yervoy, Rybrevant, Carvykti Lead New Additions | Italy Pharma | News | iPharmaCenter
Badari Andukuri
May 27
Eli Lilly Expands Infectious Disease Pipeline Through Strategic Biotech Acquisitions | iPharmaCenter
Badari Andukuri
May 26
European Atherosclerosis Society (EAS) Congress | 2026 | News | Updates | iPharmaCenter
Badari Andukuri
May 25
Germany Advances Pharmacy Reform with ApoVWG Law to Strengthen Rural Access and Healthcare Services
Badari Andukuri
May 25
FDA Approves Datroway as First TROP2-Directed ADC for First-Line Metastatic Triple-Negative Breast Cancer in Non-PD-1/PD-L1 Candidates
ipharmaservices
May 22
Europe’s Pharmaceutical Strategy in a Changing Global Order: Germany and France Push for Resilience and Competitiveness | iPharmaCenter
Badari Andukuri
May 22
Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial | iPharmaCenter
Badari Andukuri
May 22
Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter
Badari Andukuri
May 21
Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter
Badari Andukuri
May 21
Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter
Badari Andukuri
May 18
American Urological Association Annual Meeting 2026 | News | Updates | iPharmaCenter
ipharmaservices
May 18
BeOne Medicines’ Beqalzi (sonrotoclax) Gets FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma | iPharmaCenter
Badari Andukuri
May 16
AstraZeneca Introduces K+ Connect Program Across India for Hyperkalemia Management
Badari Andukuri
May 15
NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer
ipharmaservices
May 14
bottom of page
